Researchers are Testing a New Medicine That Could Reduce Anxiety and Other Autism Challenges - The Autism Site News
PDF) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model - ScienceDirect
NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model - ScienceDirect
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model - ScienceDirect
(PDF) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
Frontiers | Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research | Neuroscience
IJMS | Free Full-Text | Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases | HTML
On the spectrum of hope - Scripps Research Magazine
A drug candidate holds promise in treating autism - Cusabio
NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models | Molecular Psychiatry
NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models | Request PDF
In human mini-brain experiments, drug preserves and rebuilds nerve connections that are lost to Alzheimer's | Scripps Research
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
The BRAIN Foundation - Potential of MEF2 Transcriptional Activator Therapy for ASD Phenotypes - STUART LIPTON, MD, PhD Hannah and Eugene Step Chair; Professor; Co-director, Neuroscience Translational Center Department of Molecular Medicine,
Human Neurons from Ctrl- and AD-Patient-Derived iPSCs Are Resistant to... | Download Scientific Diagram
On the spectrum of hope - Scripps Research Magazine
PDF) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
Monthly Research Review – January 2021 – The Science of Parkinson's
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
NitroSynapsin inhibits spontaneous calcium activity and 0.2–1 Hz events... | Download Scientific Diagram
Aberrant gliogenesis and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids | bioRxiv
New Autism Drug Shows Promise in Preclinical Study | Medicilon Inc
New Autism Drug Shows Promise in Preclinical Study
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
